Trial Profile

Phase I/II study of NS-87 in patients with high risk acute myeloid leukemia.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Nippon Shinyaku

Most Recent Events

26 Mar 2024 According to a Nippon Shinyaku media release, based on the data from the Phase III trial conducted by Jazz Pharmaceuticals and a Phase I/II trial conducted by Nippon Shinyaku, the Ministry of Health, Labour and Welfare (MHLW) has approved Vyxeos Combination for I.V. Injection (Daunorubicin hydrochloride/cytarabine liposomal drug for injection) for the treatment of high-risk acute myeloid leukemia (AML) in Japan.
05 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com